Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) con...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicholson, R. I., Maynard, P. V.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1979
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009890/
https://www.ncbi.nlm.nih.gov/pubmed/380618
_version_ 1782136207176630272
author Nicholson, R. I.
Maynard, P. V.
author_facet Nicholson, R. I.
Maynard, P. V.
author_sort Nicholson, R. I.
collection PubMed
description Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) content. Twice daily i.m. injections of either 5 micrograms or 0.5 micrograms ICI 118630 in saline were as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+ DMBA-induced mammary tumours. ER- mammary tumours showed a more equivocal overall response to ICI 118630, some tumours progressing, others regressing. About one-third of the ER+ tumours disappeared in the 20-day treatment period. Those tumours which did regrow after the cessation of treatment proved to be hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on pre-existing tumours, ICI 118630 also reduced the total number of new tumours formed during and after treatment.
format Text
id pubmed-2009890
institution National Center for Biotechnology Information
language English
publishDate 1979
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20098902009-09-10 Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Nicholson, R. I. Maynard, P. V. Br J Cancer Research Article Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) content. Twice daily i.m. injections of either 5 micrograms or 0.5 micrograms ICI 118630 in saline were as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+ DMBA-induced mammary tumours. ER- mammary tumours showed a more equivocal overall response to ICI 118630, some tumours progressing, others regressing. About one-third of the ER+ tumours disappeared in the 20-day treatment period. Those tumours which did regrow after the cessation of treatment proved to be hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on pre-existing tumours, ICI 118630 also reduced the total number of new tumours formed during and after treatment. Nature Publishing Group 1979-03 /pmc/articles/PMC2009890/ /pubmed/380618 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Nicholson, R. I.
Maynard, P. V.
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title_full Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title_fullStr Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title_full_unstemmed Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title_short Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
title_sort anti-tumour activity of ici 118630, a new potent luteinizing hormone-releasing hormone agonist.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009890/
https://www.ncbi.nlm.nih.gov/pubmed/380618
work_keys_str_mv AT nicholsonri antitumouractivityofici118630anewpotentluteinizinghormonereleasinghormoneagonist
AT maynardpv antitumouractivityofici118630anewpotentluteinizinghormonereleasinghormoneagonist

Ejemplares similares